Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.
Jia LiuMin-Jiang ChenXiaoxing GaoXiaoyan LiuJing ZhaoRuili PanWei ZhongYan XuMengzhao WangPublished in: Thoracic cancer (2023)
This trial will provide evidence of the benefit and safety of pembrolizumab in combination with plinabulin and docetaxel in metastatic NSCLC patients who have been exposed and developed resistance to first-line PD-1/PD-L1 inhibitor either as monotherapy or in combination with chemotherapy.
Keyphrases
- study protocol
- locally advanced
- small cell lung cancer
- open label
- advanced non small cell lung cancer
- newly diagnosed
- randomized controlled trial
- squamous cell carcinoma
- clinical trial
- end stage renal disease
- ejection fraction
- prognostic factors
- rectal cancer
- phase ii
- phase iii
- double blind
- patient reported
- brain metastases